Aileron Therapeutics マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

James Windsor

最高経営責任者

US$715.9k

報酬総額

CEO給与比率	11.9%
CEO在任期間	1.1yrs
CEOの所有権	0.03%
経営陣の平均在職期間	データなし
取締役会の平均在任期間	6.2yrs

経営陣の近況

Recent updates

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aug 18

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Dec 30

CEO報酬分析

Aileron Therapeutics の収益と比較して、James Windsor の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$29m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$18m
Dec 31 2023	US$716k	US$85k	-US$16m

報酬と市場: Jamesの総報酬 ($USD 715.92K ) は、 US市場 ($USD 653.78K ) の同様の規模の企業の平均とほぼ同じです。

報酬と収益: Jamesの報酬と会社の業績を比較するにはデータが不十分です。

CEO（最高経営責任者

James Windsor (58 yo)

1.1yrs

在職期間

US$715,921

報酬

Dr. James Brian Windsor, Ph.D. is Chief Executive Officer and Director of Aileron Therapeutics, Inc. from March 11, 2024 and its President. Dr. Windsor served as Chief Operating Officer and President from...

取締役

名称	ポジション	在職期間	報酬	所有権
James Windsor	CEO, President & Director	less than a year	US$715.92k	0.033% $ 19.7k
Josef von Rickenbach	Independent Chairman	5.4yrs	US$67.97k	0.10% $ 61.5k
Alan Musso	Independent Director	1.1yrs	US$15.64k	0% $ 0
Carol Prives	Member of Scientific Advisory Board	6.7yrs	データなし	データなし
Brian Druker	Member of Scientific Advisory Board	6.7yrs	データなし	データなし
Alan List	Member of Scientific Advisory Board	6.7yrs	データなし	データなし
Reinhard Ambros	Independent Lead Director	11.4yrs	US$46.25k	0.0013% $ 801.3
William Fairey	Independent Director	1.1yrs	US$9.38k	0% $ 0
Manuel Aivado	Director	6.2yrs	US$630.74k	0.00023% $ 137.5
Ulrich Steidl	Member of Scientific Advisory Board	no data	データなし	データなし

6.2yrs

平均在職期間

65.5yo

平均年齢

経験豊富なボード: ALRNの取締役会は経験豊富であると考えられます ( 6.2年の平均在任期間)。

Aileron Therapeutics マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Aileron Therapeutics, Inc. Announces CFO Changes

Aileron Therapeutics, Inc. Announces CEO Changes

Aileron Therapeutics, Inc., Annual General Meeting, Feb 28, 2024

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

New major risk - Financial position

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

New major risk - Share price stability

New minor risk - Share price stability

Aileron Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 44% to US$13.00

Aileron Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Aileron Therapeutics, Inc. announced delayed annual 10-K filing

Aileron Therapeutics, Inc. Announces CFO Changes

Aileron Therapeutics, Inc. Announces CEO Changes

Aileron Therapeutics, Inc., Annual General Meeting, Feb 28, 2024

Aileron Therapeutics Receives Non-Compliance Notice from Nasdaq

New major risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Share price stability

New minor risk - Shareholder dilution

Aileron Therapeutics, Inc. (NasdaqCM:ALRN) acquired Lung Therapeutics, Inc.

Aileron Therapeutics, Inc. announced that it expects to receive $16.4 million in funding from Nantahala Capital Management, LLC and other investors

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

Insufficient new directors

Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aileron Therapeutics Outlines Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

Insufficient new directors

Insufficient new directors

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN 6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

Aileron Therapeutics Appoints Susan L. Drexler as Interim Chief Financial Officer

Aileron Therapeutics, Inc. Appoints Manuel Aivado as Principal Financial Officer and Principal Accounting Officer

Aileron Therapeutics Announces First Patients Treated in Phase 1B Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

Aileron Therapeutics, Inc. Announces Resignation of Richard J. Wanstall as Chief Financial Officer, Effective from May 6, 2022

Price target decreased to US$2.00

Less than half of directors are independent

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$2.00

Less than half of directors are independent

Aileron Therapeutics: An Assessment On A Lottery Ticket

Aileron Therapeutics, Inc. Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics: Solving Chemotherapy's Toxicity

Aileron Therapeutics, Inc. Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $35.894081 million.

Aileron Therapeutics +31% on insider buying more shares

Aileron raises $40M via equity offering

Aileron Therapeutics EPS in-line

Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.762 million.

Aileron Therapeutics, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Aileron Therapeutics, Inc.(NasdaqCM:ALRN) dropped from Russell Microcap Value Index

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24